ALRN
$1.23
Aileron Therapeutics
($.10)
(7.52%)
ALRN
Earnings Whisper ®
N/A
3rd Quarter September 2020
Consensus:  ($0.10)
Revenue:  $0.00 Mil
Wednesday
Nov 4
Before the open
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when ALRN reports earnings?
Beat
Meet
Miss

Where is ALRN's stock price going from here?
Up
Flat
Down
Stock chart of ALRN
Analysts
Summary of analysts' recommendations for ALRN
Score
Grade
Pivots
Resistance
$1.49
$1.44
$1.33

$1.28

Support
$1.17
$1.12
$1.01
Tweet
Growth
Description
Aileron Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It engages in developing and commercializing a novel class of therapeutics primarily in the United States. The companys lead product includes ALRN-6924, targets the tumor suppressor protein p53 for the treatment of a range of cancers which are in clinical stage. Aileron Therapeutics, Inc. is based in Cambridge, Massachusetts.